CharlieS, I recognized you from the VIDA board. That's been a struggle! Still hanging in?
Im still trying to figure out Hyseq, and differentiate it from AFFX, which is my only gene chip holding. Seems like there may be some applications for the limited sequencing HYSQ chips can do, but these are mostly in the area of rtesearch, rather than drug discovery and development. I need to get the prospectus.
Revenues are minor so far, except for the Chiron/PE partnerships. Their market cap is about $200 mil (9.5 m shares x $20+/sh), about 1/5th of AFFX. I think its tough to evaluate where HYSQ might go, but it could move up with AFFX in sympathy, in spite of any fundamentals or lack therof. There seems to be an enormous demand for AFFX chips, and this may be interpreted as good news for HYSQ and Synteni too.
But, If AFFX stumbles, look out. |
